NAVIDEA BIOPHARMACEUTICALS, INC.

Basic Information

5600 BLAZER PKWY STE 200
DUBLIN, OH, 43017-7550

http://www.navidea.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 131891467
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 57


  1. 99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries

    Amount: $165,917.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals (Navidea) is seeking SBIR FastTrack grant support to investigate the clinical utility, safety, and efficacy of its new product, 99mTc-ti ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology

    Amount: $1,572,900.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing 18F-AZD4694 as a diagnostic imaging agent to be used with PET scans to directly visualize beta amyloid (A?) deposits in th ...

    SBIR Phase II 2014 Department of Health and Human Services
  3. [18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia

    Amount: $2,032,234.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing [18F]NAV4694 as a diagnostic imaging agent that can be used to visualize beta-amyloid (A) plaques in the brains of living ...

    SBIR Phase II 2014 Department of Health and Human Services
  4. Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology

    Amount: $258,824.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing 18F-AZD4694 as a diagnostic imaging agent to be used with PET scans to directly visualize beta amyloid (A ) deposits in th ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. A peripheral diagnostic biomarker for Major Depressive Disorder

    Amount: $151,814.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing [18F]NAV4694 as a diagnostic imaging agent that can be used to visualize beta-amyloid (A) plaques in the brains of living ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv

    Amount: $315,217.00

    DESCRIPTION (provided by applicant): After an interim period of inactivity based on a select alternative commercial focus, and after consultation with the FDA, Neoprobe Corporation is rapidly reinitia ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government